Table 4.
Reduction in biopsies/cancers detected, as compared with the current study, using as a threshold for biopsy a 20% or higher probability of cancer
| Number of biopsies | Number of cancers | Number of high-grade cancers | ||||
| Performed | Reduced (%) | Caught | Missed (%) | Caught | Missed (%) | |
| Biopsy all | 740 | n/a | 192 | n/a | 40 | n/a |
| Laboratory model | ||||||
| Base | 489 | 251 (34%) | 153 | 39 (20%) | 38 | 2 (5%) |
| Base+free PSA | 380 | 360 (49%) | 152 | 40 (21%) | 36 | 4 (10%) |
| Full | 316 | 424 (57%) | 161 | 31 (16%) | 37 | 3 (8%) |
| Clinical model | ||||||
| Base | 344 | 396 (54%) | 136 | 56 (29%) | 37 | 3 (8%) |
| Base+free PSA | 336 | 404 (55%) | 147 | 45 (23%) | 38 | 2 (5%) |
| Full | 297 | 443 (60%) | 159 | 33 (17%) | 39 | 1 (3%) |
The base model for the laboratory model includes age and total prostate specific antigen (PSA), and for the clinical model includes age, total PSA, and digital rectal examination result. The full model includes the base model plus free PSA, intact PSA, and human kallikrein 2. Cancers with biopsy Gleason score 7 and higher were considered high grade. Percentages given in parentheses represent the percentage as compared with the current study.